{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:55:02Z","timestamp":1769572502170,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T00:00:00Z","timestamp":1532822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10067-018-4238-4","type":"journal-article","created":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T18:34:36Z","timestamp":1532802876000},"page":"2741-2749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-7401","authenticated-orcid":false,"given":"Michele Maria","family":"Luchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devis","family":"Benfaremo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Molinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Ciferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Cataldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Capeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Salaffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,29]]},"reference":[{"key":"4238_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"C Ritchlin","year":"2017","unstructured":"Ritchlin C, Colbert R, Gladman D (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970. \n                    https:\/\/doi.org\/10.1056\/nejmra1505557","journal-title":"N Engl J Med"},{"key":"4238_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"N McHugh","year":"2003","unstructured":"McHugh N (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778\u2013783. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keg217","journal-title":"Rheumatology"},{"key":"4238_CR3","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/art.34536","volume":"64","author":"L Coates","year":"2012","unstructured":"Coates L, Conaghan P, Emery P et al (2012) Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 64:3150\u20133155. \n                    https:\/\/doi.org\/10.1002\/art.34536","journal-title":"Arthritis Rheum"},{"key":"4238_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783. \n                    https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"key":"4238_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J (2010) The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25\u201331. \n                    https:\/\/doi.org\/10.1136\/ard.2010.133645","journal-title":"Ann Rheum Dis"},{"key":"4238_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2015","unstructured":"Gossec L, Smolen J, Ramiro S et al (2015) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"key":"4238_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"L Coates","year":"2016","unstructured":"Coates L, Kavanaugh A, Mease P et al (2016) Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum 68:1060\u20131071. \n                    https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheum"},{"key":"4238_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.adengl.2013.07.003","volume":"105","author":"J Ca\u00f1ete","year":"2014","unstructured":"Ca\u00f1ete J, Daud\u00e9n E, Queiro R et al (2014) Recommendations for the coordinated Management of Psoriatic Arthritis by rheumatologists and dermatologists: a Delphi study. Actas Dermo-Sifiliogr\u00e1ficas (English Edition) 105:216\u2013232. \n                    https:\/\/doi.org\/10.1016\/j.adengl.2013.07.003","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"4238_CR9","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1007\/s12325-016-0429-z","volume":"33","author":"J Gratacos-Masmitja","year":"2016","unstructured":"Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, Botella-Estrada R, Carrizosa-Esquivel AM, Garcia-Vivar ML, Perez-Barrio S, Roman-Ivorra JA, Ruiz-Montesino MD, Lopez-Estebaranz JL (2016) Points to consider in the Foundation of Multidisciplinary Units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther 33:2150\u20132159. \n                    https:\/\/doi.org\/10.1007\/s12325-016-0429-z","journal-title":"Adv Ther"},{"key":"4238_CR10","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.jaad.2005.10.052","volume":"54","author":"K Gordon","year":"2006","unstructured":"Gordon K, Ruderman E (2006) The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 54:S85\u2013S91. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2005.10.052","journal-title":"J Am Acad Dermatol"},{"key":"4238_CR11","first-page":"127","volume":"36","author":"F Salaffi","year":"2018","unstructured":"Salaffi F, Di Carlo M, Luchetti MM et al (2018) A validation study of the simple psoriatic arthritis screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 36:127\u2013135","journal-title":"Clin Exp Rheumatol"},{"key":"4238_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, de Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774\u2013790. \n                    https:\/\/doi.org\/10.1111\/jdv.14114","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4238_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7525-7-25","volume":"7","author":"F Salaffi","year":"2009","unstructured":"Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25. \n                    https:\/\/doi.org\/10.1186\/1477-7525-7-25","journal-title":"Health Qual Life Outcomes"},{"key":"4238_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150\u20131157. \n                    https:\/\/doi.org\/10.1136\/ard.2004.032268","journal-title":"Ann Rheum Dis"},{"key":"4238_CR15","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P Mease","year":"2004","unstructured":"Mease P, Kivitz A, Burch F et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264\u20132272. \n                    https:\/\/doi.org\/10.1002\/art.20335","journal-title":"Arthritis Rheum"},{"key":"4238_CR16","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman D, Husted J et al (1997) Mortality studies in psoriatic arthritis. Results from a single outpatient clinic I Causes and risk of death. Arthritis Rheum 40:1868\u20131872. \n                    https:\/\/doi.org\/10.1002\/art.1780401021","journal-title":"Arthritis Rheum"},{"key":"4238_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3899\/jrheum.120836","volume":"40","author":"J Walsch","year":"2013","unstructured":"Walsch J, Callis Duffin K, Krueger G, Clegg D (2013) Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol 40:287\u2013293. \n                    https:\/\/doi.org\/10.3899\/jrheum.120836","journal-title":"J Rheumatol"},{"key":"4238_CR18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","volume":"72","author":"M Haroon","year":"2012","unstructured":"Haroon M, Kirby B, FitzGerald O (2012) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 72:736\u2013740. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-201706","journal-title":"Ann Rheum Dis"},{"key":"4238_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"G Kingsley","year":"2012","unstructured":"Kingsley G, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 51:1368\u20131377. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology"},{"key":"4238_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"P Mease","year":"2009","unstructured":"Mease P, Ory P, Sharp J et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 68:702\u2013709. \n                    https:\/\/doi.org\/10.1136\/ard.2008.092767","journal-title":"Ann Rheum Dis"},{"key":"4238_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986. \n                    https:\/\/doi.org\/10.1002\/art.24403","journal-title":"Arthritis Rheum"},{"key":"4238_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"P Mease","year":"2013","unstructured":"Mease P, Fleischmann R, Deodhar A et al (2013) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48\u201355. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696","journal-title":"Ann Rheum Dis"},{"key":"4238_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"I McInnes","year":"2013","unstructured":"McInnes I, Kavanaugh A, Gottlieb A et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(13)60594-2","journal-title":"Lancet"},{"key":"4238_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"P Mease","year":"2015","unstructured":"Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landew\u00e9 R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329\u20131339. \n                    https:\/\/doi.org\/10.1056\/nejmoa1412679","journal-title":"N Engl J Med"},{"key":"4238_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"P Mease","year":"2016","unstructured":"Mease P, van der Heijde D, Ritchlin C, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, SPIRIT-P1 Study Group (2016) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79\u201387. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709","journal-title":"Ann Rheum Dis"},{"key":"4238_CR26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease P, Gomez-Reino J et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020\u20131026. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-205056","journal-title":"Ann Rheum Dis"},{"key":"4238_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2174\/1389201019666171226151852","volume":"18","author":"M Luchetti","year":"2018","unstructured":"Luchetti M, Benfaremo D, Gabrielli A (2018) Biologics in inflammatory and Immunomediated arthritis. Curr Pharm Biotechnol 18:989\u20131007. \n                    https:\/\/doi.org\/10.2174\/1389201019666171226151852","journal-title":"Curr Pharm Biotechnol"},{"key":"4238_CR28","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.3748\/wjg.v23.i39.7139","volume":"23","author":"M Luchetti","year":"2017","unstructured":"Luchetti M, Benfaremo D, Ciccia F et al (2017) Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. World J Gastroenterol 23:7139\u20137149. \n                    https:\/\/doi.org\/10.3748\/wjg.v23.i39.7139","journal-title":"World J Gastroenterol"},{"key":"4238_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.sder.2005.01.006","volume":"24","author":"A Qureshi","year":"2005","unstructured":"Qureshi A, Husni M, Mody E (2005) Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 24:46\u201351. \n                    https:\/\/doi.org\/10.1016\/j.sder.2005.01.006","journal-title":"Semin Cutan Med Surg"},{"key":"4238_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00296-015-3377-z","volume":"36","author":"T Cobo-Ib\u00e1\u00f1ez","year":"2015","unstructured":"Cobo-Ib\u00e1\u00f1ez T, Villaverde V, Seoane-Mato D, Mu\u00f1oz-Fern\u00e1ndez S, Guerra M, del Campo PD, Ca\u00f1ete JD (2015) Multidisciplinary dermatology\u2013rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int 36:221\u2013229. \n                    https:\/\/doi.org\/10.1007\/s00296-015-3377-z","journal-title":"Rheumatol Int"},{"key":"4238_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00403-011-1172-6","volume":"304","author":"N Velez","year":"2011","unstructured":"Velez N, Wei-Passanese E, Husni M et al (2011) Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res 304:7\u201313. \n                    https:\/\/doi.org\/10.1007\/s00403-011-1172-6","journal-title":"Arch Dermatol Res"},{"key":"4238_CR32","doi-asserted-by":"publisher","first-page":"AB180","DOI":"10.1016\/j.jaad.2014.01.746","volume":"70","author":"S P\u00e9rez-Barrio","year":"2014","unstructured":"P\u00e9rez-Barrio S, Galindez E, Alzaga J (2014) Psoriasis and psoriatic arthropathy multidisciplinary clinic at Basurto University hospital: 2 years of experience. J Am Acad Dermatol 70:AB180. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2014.01.746","journal-title":"J Am Acad Dermatol"},{"key":"4238_CR33","first-page":"38","volume":"167","author":"A Foulkes","year":"2012","unstructured":"Foulkes A, Chinoy H, Warren RB (2012) High degree of patient satisfaction and exceptional feedback in a specialist combined dermatology and rheumatology clinic. Br J Dermatol 167:38","journal-title":"Br J Dermatol"},{"key":"4238_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s10067-017-3937-6","volume":"37","author":"M Carlo Di","year":"2017","unstructured":"Di Carlo M, Luchetti M, Benfaremo D et al (2017) The DETection of arthritis in inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 37:1037\u20131044. \n                    https:\/\/doi.org\/10.1007\/s10067-017-3937-6","journal-title":"Clin Rheumatol"},{"key":"4238_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3899\/jrheum.170833","volume":"45","author":"M Luchetti","year":"2018","unstructured":"Luchetti M, Ciccia F, Avellini C et al (2018) Sclerostin and Antisclerostin antibody serum levels predict the presence of axial Spondyloarthritis in patients with inflammatory bowel disease. J Rheumatol 45:630\u2013637. \n                    https:\/\/doi.org\/10.3899\/jrheum.170833","journal-title":"J Rheumatol"},{"key":"4238_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0950-3579(94)80024-3","volume":"8","author":"D Gladman","year":"1994","unstructured":"Gladman D (1994) Natural history of psoriatic arthritis. Bailli\u00e8re's Clin Rheumatol 8:379\u2013394. \n                    https:\/\/doi.org\/10.1016\/s0950-3579(94)80024-3","journal-title":"Bailli\u00e8re's Clin Rheumatol"},{"key":"4238_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1468-3083.2009.03159.x","volume":"23","author":"M Radtke","year":"2009","unstructured":"Radtke M, Reich K, Blome C, Rustenbach S, Augustin M (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23:683\u2013691. \n                    https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03159.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4238_CR38","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460\u20131468. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keg384","journal-title":"Rheumatology"},{"key":"4238_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjd.12190","volume":"168","author":"L Coates","year":"2013","unstructured":"Coates L, Aslam T, Al Balushi F et al (2013) Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 168:802\u2013807. \n                    https:\/\/doi.org\/10.1111\/bjd.12190","journal-title":"Br J Dermatol"},{"key":"4238_CR40","doi-asserted-by":"publisher","unstructured":"Karreman M, Weel A, van der Ven M et al (2016) Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology kew410. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew410","DOI":"10.1093\/rheumatology\/kew410"},{"key":"4238_CR41","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","volume":"52","author":"L Coates","year":"2013","unstructured":"Coates L, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes I, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh N, BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology 52:1754\u20131757. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket187","journal-title":"Rheumatology"},{"key":"4238_CR42","doi-asserted-by":"publisher","first-page":"e6712","DOI":"10.1136\/bmj.e6712","volume":"345","author":"E Samarasekera","year":"2012","unstructured":"Samarasekera E, Sawyer L, Parnham J, Smith C (2012) Assessment and management of psoriasis: summary of NICE guidance. BMJ 345:e6712\u2013e6712. \n                    https:\/\/doi.org\/10.1136\/bmj.e6712","journal-title":"BMJ"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4238-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T19:03:49Z","timestamp":1564340629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4238-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,29]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4238"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4238-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,29]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This work was conducted in accordance with the ethical principles of the Helsinki Declaration of 1975 and revised in 1983, and in accordance with the ethical standards of the institutional responsible committee on human experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}